Avantor, Inc. (NYSE:AVTR – Free Report) – Analysts at Zacks Research lowered their Q3 2025 earnings estimates for shares of Avantor in a note issued to investors on Thursday, September 19th. Zacks Research analyst D. Dey now anticipates that the company will post earnings per share of $0.29 for the quarter, down from their previous forecast of $0.30. The consensus estimate for Avantor’s current full-year earnings is $1.01 per share.
Avantor (NYSE:AVTR – Get Free Report) last issued its quarterly earnings results on Friday, July 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.02. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Avantor had a net margin of 5.28% and a return on equity of 12.40%.
View Our Latest Research Report on AVTR
Avantor Price Performance
Shares of AVTR opened at $26.58 on Monday. The stock has a market capitalization of $18.05 billion, a P/E ratio of 68.15, a P/E/G ratio of 2.75 and a beta of 1.32. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89. Avantor has a twelve month low of $16.63 and a twelve month high of $28.00. The company has a 50 day moving average of $25.16 and a 200-day moving average of $24.36.
Insider Transactions at Avantor
In related news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares in the company, valued at $740,372.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.50% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Boston Partners grew its position in Avantor by 2.2% in the first quarter. Boston Partners now owns 28,561,802 shares of the company’s stock valued at $729,298,000 after acquiring an additional 624,369 shares during the last quarter. Canada Pension Plan Investment Board grew its position in Avantor by 6.8% in the second quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock valued at $486,059,000 after acquiring an additional 1,463,695 shares during the last quarter. Artemis Investment Management LLP grew its position in Avantor by 14.9% in the first quarter. Artemis Investment Management LLP now owns 9,120,083 shares of the company’s stock valued at $233,109,000 after acquiring an additional 1,180,937 shares during the last quarter. 1832 Asset Management L.P. grew its position in Avantor by 1,634.9% in the second quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock valued at $180,839,000 after acquiring an additional 8,038,451 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in Avantor by 4.4% in the first quarter. Bessemer Group Inc. now owns 7,099,848 shares of the company’s stock valued at $181,544,000 after acquiring an additional 297,534 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.
Avantor Company Profile
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Featured Articles
- Five stocks we like better than Avantor
- What is Short Interest? How to Use It
- The Average 401k Balance by Age Explained
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Profitably Trade Stocks at 52-Week Highs
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.